Nileshkumar Meghani

Nileshkumar Meghani has over 10 years of experience in the pharmaceutical industry. From 2021 to present, they have been working as a Postdoctoral Research Scientist at Inimmune, where they have been spearheading the formulation development of novel STING agonists as vaccine adjuvants and performing method development for HPLC quantification and analytical characterization of the developed liposomes and lipid nanoparticle formulations. Nileshkumar has also been involved in the development of vaccines for the treatment of Opioid use disorder, performing and optimizing conjugation of hapten adjuvants on the CRM protein by EDC/NHS chemistry and completing initial in vivo screening of formulated conjugates for murine immunogenicity studies. From 2020 to 2021, Nileshkumar worked as a Senior and Formulation Scientist at Sam Chun Dang Pharm. Co. Ltd. From 2019 to 2020, they worked as a Formulation Scientist at Alvogen, where they were involved in research and development of sustained/prolonged-release tablets as well as immediate release bilayer tablets, and prototype development of tablets based on Oral Controlled Absorption System (OCAS) technology. In 2019, they also worked as a Postdoctoral Researcher at Jeju National University, Republic of Korea, where they designed and evaluated Organ-on-a-chip (lung-chip, liver-chip, and Kidney-chip) with and without in-built embedded sensors (i.e., TEER, pH, ROS) for pharma and biopharmaceutical applications. From 2018 to 2019, Nileshkumar worked as a Postdoctoral Research Fellow at Ajou University, where they performed and managed the World Health Organization (WHO) project on equilibrium solubility experiments for the purpose of BCS classification of active pharmaceutical ingredients (API) for biowaiver, designed novel experiments for evaluation of nanoparticles under biomimetic conditions of microfluidic shear stress and protein corona, and formulated development of poorly water soluble drugs (BCS class II and IV) through solid dispersion solubilization approaches, 3D printing, etc. From 2012 to 2011, they worked as a Senior Pharmacovigilance Associate at Tata Consultancy Services, where they monitored and reported safety reports of Oncology clinical trials for the Roche Pharmaceutical, UK. In 2011, they worked as a Clinical Research Coordinator at Bharat Cancer Hospital & Research Institute, where they planned and executed clinical trials for phase 2 and 3 for safety, efficacy and BA/BE studies. Finally, from 2010 to 2011, Nileshkumar worked as a Research Intern at Wockhardt Ltd., where they carried out dissertation research work on “Toxicity assessment of Clarithromycin in diabetic wistar rats treated with Rosiglitazone”, conducted efficacy and toxicity studies of Erythropoietin, Insulin Glargine (rDNA) origin on mice, rats and rabbits under good laboratory practice (GLP) environment, and performed pharmacokinetic studies of in-house new chemical entities (NCEs) on mice, rats, rabbits and beagle dogs.

Nileshkumar Meghani has a comprehensive education history. Nileshkumar obtained a Bachelor's Degree in Pharmacy from Rajiv Gandhi University of Health Sciences in 2008, followed by a Master's Degree in Pharmacology from SVKM's Narsee Monjee Institute of Management Studies (NMIMS) in 2011. Finally, in 2018 they obtained a Ph.D. in Pharmaceutics and Drug Delivery from Ajou University.